---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-22-000098"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:40:57.459101+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Agios Q3 2022: PYRUKYND revenue $3.5M, 56 patients on therapy; CHMP positive opinion received

## Summary
- PYRUKYND net revenue $3.5M in Q3 2022; 56 patients on therapy (+51% Q/Q), 84 patients enrolled (+64%).
- Received positive CHMP opinion for PYRUKYND in adult PK deficiency; filed with UK MHRA.
- Cash $1.0B as of Sept 30; subsequently received $131.8M from sale of TIBSOVO royalty rights.
- Net loss from continuing ops $81.7M vs $84.3M in Q3 2021; R&D $65.0M, SG&A $29.1M.
- Appointed Cecilia Jones as CFO; Rahul Ballal and Cynthia Smith to board of directors.

## SEC filing metadata
- accession: 0001439222-22-000098
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922222000098/0001439222-22-000098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922222000098/agio-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-22-000098
- JSON: https://secwatch.observer/filing/0001439222-22-000098.json
- Plain text: https://secwatch.observer/filing/0001439222-22-000098.txt

## Key facts
- Earnings Releases
  AGIOS PHARMACEUTICALS, INC. reported third quarter ended September 30, 2022 results: revenue $3.5 million, net income Net loss from continuing operations was $81.7 million.
  - Period: third quarter ended September 30, 2022
  - Revenue: $3.5 million
  - Net income: Net loss from continuing operations was $81.7 million
  - Result: reported results
  source text: Quarter 2022 Financial Results – U.S. PYRUKYND ® (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion; Net Revenue of $3.5 Million in Q3 – – Received Positive CHMP Opinion for PYRUKYND ® in Adults with Pyruvate Kinase (PK) Deficiency – – On Track to Meet Year-end Enrollment Targets in PYRUKYND ® Thalassemia
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000143922222000098/0001439222-22-000098-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.